novel targeted cancer treatments

Kura hit as FDA slaps partial hold on leukaemia trial

Share in Kura Oncology have come under pressure after a patient death in a clinical trial of the US biotech’s acute myeloid leukaemia (AML) therapy KO-539, provisionally attributed to a side effect that plagues other drugs used to treat the cancer. The FDA has placed the trial on partial hold, meaning that patients already in …

Kura hit as FDA slaps partial hold on leukaemia trial Read More »

Trial flop busts Deciphera’s blockbuster hopes for Qinlock

Shares in Deciphera Pharma went into freefall on Friday after top-line results of a phase 3 trial of its Qinlock in rare cancer gastrointestinal stromal tumour (GIST) dashed its hopes of moving the drug earlier in treatment. KIT inhibitor Qinlock (ripretinib) was by the FDA last year as a fourth-line therapy for GIST in adults …

Trial flop busts Deciphera’s blockbuster hopes for Qinlock Read More »

Novartis’ ‘wild card’ drug Scemblix gets FDA nod for leukaemia

Novartis has claimed FDA approval for one of its ‘wild card’ drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML). Scemblix (asciminib) was one of a clutch of high risk, high reward drug candidates for a range of diseases that Novartis chief executive Vas Narasimhan said last year …

Novartis’ ‘wild card’ drug Scemblix gets FDA nod for leukaemia Read More »

FDA starts quick review of Merck’s MET-targeting lung cancer drug

Merck KGaA could be looking at an early 2021 approval for its MET inhibitor tepotinib in lung cancer from the FDA after the US regulator started a priority review of the drug, but could still be beaten to market by a rival drug. Tepotinib has been developed to treat non-small cell lung cancer (NSCLC) with …

FDA starts quick review of Merck’s MET-targeting lung cancer drug Read More »

Novartis eyes filings for leukaemia drug asciminib after phase 3 win

A first-in-class STAMP inhibitor developed by Novartis – asciminib – has outperformed a current drug for chronic myeloid leukaemia (CML) in a head-to-head trial, setting up regulatory filings. The ASCEMBL trial compared asciminib (ABL001) to Pfizer’s Bosulif (bosutinib) in Philadelphia chromosome-positive CML patients who had previously been treated with two or more tyrosine kinase inhibitors …

Novartis eyes filings for leukaemia drug asciminib after phase 3 win Read More »